Bifogade filer
NET ASSET VALUE – 31 December 2025
2026-01-09 08:00:00
On the 31 December 2025 Flerie AB's Net Asset Value (NAV) was SEK 3,377 million and NAV per share was SEK 43.60.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 250 | 3.23 | 7.4% |
| Xspray Pharma | 18% | 228 | 2.95 | 6.8% |
| Empros Pharma | 79% | 204 | 2.64 | 6.1% |
| Lipum | 57% | 198 | 2.56 | 5.9% |
| Atrogi | 44% | 197 | 2.54 | 5.8% |
| KAHR Medical | 35% | 168 | 2.16 | 5.0% |
| Bonsai Biotherapeutics | 100% | 152 | 1.96 | 4.5% |
| Xintela | 60% | 143 | 1.84 | 4.2% |
| Microbiotica | 10% | 124 | 1.60 | 3.7% |
| AnaCardio | 13% | 79 | 1.02 | 2.3% |
| Mendus | 23% | 78 | 1.01 | 2.3% |
| EpiEndo Pharmaceuticals | 9% | 54 | 0.69 | 1.6% |
| Vitara Biomedical | 11% | 52 | 0.67 | 1.5% |
| Geneos Therapeutics | 12% | 34 | 0.43 | 1.0% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.41 | 0.9% |
| Egetis Therapeutics | 1% | 26 | 0.33 | 0.8% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.14 | 0.3% |
| Alder Therapeutics | 30% | 0 | 0.00 | 0.0% |
| Total | 2,039 | 26.33 | 60.4% | |
| Commercial Growth | ||||
| NorthX Biologics | 61% | 202 | 2.61 | 6.0% |
| Symcel | 30% | 192 | 2.48 | 5.7% |
| Chromafora | 28% | 131 | 1.69 | 3.9% |
| Nanologica | 44% | 30 | 0.38 | 0.9% |
| Frontier Biosolutions | 2% | 26 | 0.34 | 0.8% |
| Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
| Total | 581 | 7.49 | 17.2% | |
| Assets related to Portfolio companies | 213 | 2.75 | 6.3% | |
| Other assets and liabilities | 544 | 7.03 | 16.1% | |
| Net Asset Value | 3,377 | 43.60 | 100.0% | |